



Replimune to Present at Upcoming Investor Conferences

May 30, 2019

WOBURN, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members of its senior management team, will present and host investor meetings at the following two conferences.

Jefferies 2019 Global Healthcare Conference

Date: Wednesday, June 5, 2019

Presentation Time: 11:30 AM ET

Location: Grand Hyatt, New York, NY

BMO 2019 Prescriptions for Success Healthcare Conference

Date: Tuesday, June 25, 2019

Presentation Time: 11:40 AM ET

Location: Mandarin Oriental, New York, NY

About Replimune

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of “oncolytic immune-gene therapies” for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. The Company’s Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action. For more information, please visit www.replimune.com

Replimune Contact

Pamela Esposito, Ph.D.

Replimune Group, Inc.

617.233.6988

pamela@replimune.com

Investor Inquiries

Chris Brinzey

Westwicke Partners, an ICR Company

339.970.2843

chris.brinzey@westwicke.com

Media Inquiries

Arleen Goldenberg

Verge Scientific Communications

917.548.1582

agoldenberg@vergescientific.com

Source: Replimune Group Inc